KR20060103322A - 항정신병제로서의7-[4-(4-클로로벤질옥시)벤젠술포닐]-8-메톡시-3-메틸-2,3,4,5-테트라히드로-1h-3-벤즈아제피늄 말레에이트 또는토실레이트 - Google Patents

항정신병제로서의7-[4-(4-클로로벤질옥시)벤젠술포닐]-8-메톡시-3-메틸-2,3,4,5-테트라히드로-1h-3-벤즈아제피늄 말레에이트 또는토실레이트 Download PDF

Info

Publication number
KR20060103322A
KR20060103322A KR1020067010371A KR20067010371A KR20060103322A KR 20060103322 A KR20060103322 A KR 20060103322A KR 1020067010371 A KR1020067010371 A KR 1020067010371A KR 20067010371 A KR20067010371 A KR 20067010371A KR 20060103322 A KR20060103322 A KR 20060103322A
Authority
KR
South Korea
Prior art keywords
tetrahydro
methyl
methoxy
benzenesulfonyl
chlorobenzyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020067010371A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 클라팜
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20060103322A publication Critical patent/KR20060103322A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020067010371A 2003-11-28 2004-11-25 항정신병제로서의7-[4-(4-클로로벤질옥시)벤젠술포닐]-8-메톡시-3-메틸-2,3,4,5-테트라히드로-1h-3-벤즈아제피늄 말레에이트 또는토실레이트 Withdrawn KR20060103322A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327740.7A GB0327740D0 (en) 2003-11-28 2003-11-28 Novel compounds
GB0327740.7 2003-11-28

Publications (1)

Publication Number Publication Date
KR20060103322A true KR20060103322A (ko) 2006-09-28

Family

ID=29798028

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010371A Withdrawn KR20060103322A (ko) 2003-11-28 2004-11-25 항정신병제로서의7-[4-(4-클로로벤질옥시)벤젠술포닐]-8-메톡시-3-메틸-2,3,4,5-테트라히드로-1h-3-벤즈아제피늄 말레에이트 또는토실레이트

Country Status (18)

Country Link
US (1) US20070275948A1 (cg-RX-API-DMAC7.html)
EP (1) EP1687279A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007512285A (cg-RX-API-DMAC7.html)
KR (1) KR20060103322A (cg-RX-API-DMAC7.html)
CN (1) CN1906170A (cg-RX-API-DMAC7.html)
AR (1) AR046719A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004293179A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417029A (cg-RX-API-DMAC7.html)
CA (1) CA2547444A1 (cg-RX-API-DMAC7.html)
GB (1) GB0327740D0 (cg-RX-API-DMAC7.html)
IL (1) IL175663A0 (cg-RX-API-DMAC7.html)
IS (1) IS8500A (cg-RX-API-DMAC7.html)
MA (1) MA28177A1 (cg-RX-API-DMAC7.html)
NO (1) NO20062970L (cg-RX-API-DMAC7.html)
RU (1) RU2006122959A (cg-RX-API-DMAC7.html)
TW (1) TW200528433A (cg-RX-API-DMAC7.html)
WO (1) WO2005051916A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603781B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510599D0 (en) * 2005-05-24 2005-06-29 Glaxo Group Ltd Novel compounds
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
EP2240466B1 (en) * 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
CN116406268A (zh) * 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456178A1 (en) * 2001-12-21 2004-09-15 Smithkline Beecham Plc 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
PL371344A1 (en) * 2002-02-13 2005-06-13 Glaxo Group Limited Benzenesulfonamide derivatives as antipsychotic agents
MY133587A (en) * 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use

Also Published As

Publication number Publication date
WO2005051916A1 (en) 2005-06-09
CN1906170A (zh) 2007-01-31
US20070275948A1 (en) 2007-11-29
EP1687279A1 (en) 2006-08-09
JP2007512285A (ja) 2007-05-17
TW200528433A (en) 2005-09-01
IS8500A (is) 2006-06-08
AR046719A1 (es) 2005-12-21
ZA200603781B (en) 2007-09-26
MA28177A1 (fr) 2006-09-01
AU2004293179A1 (en) 2005-06-09
IL175663A0 (en) 2006-09-05
CA2547444A1 (en) 2005-06-09
RU2006122959A (ru) 2008-01-10
GB0327740D0 (en) 2003-12-31
BRPI0417029A (pt) 2007-02-06
NO20062970L (no) 2006-08-21

Similar Documents

Publication Publication Date Title
CN102066357B (zh) 作为烟碱型乙酰胆碱受体亚型α71的调节剂的吲哚衍生物
CN102292338B (zh) 酪氨酸激酶蛋白受体拮抗剂
TW200305423A (en) N-carbamoyl nitrogen-containing condensed ring compound and medicament containing same as active ingredient
TW201210582A (en) Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US11395824B2 (en) 5-HT2C receptor agonists and compositions and methods of use
WO2005047286A1 (ja) スピロ複素環化合物
BR112017023088B1 (pt) Compostos agonistas do receptor 5-ht2c, composição farmacêutica,seu processo de preparação e seus usos
TW200902026A (en) Agents for treating disorders involving modulation of ryanodine receptors
JP2019524844A (ja) 5−ht2c受容体アゴニストおよび組成物ならびに使用方法
CN102015711A (zh) 用于治疗寄生虫病的螺-吲哚衍生物
TW200806657A (en) Compounds which have activity at M1 receptor and their uses in medicine
JP2007512285A (ja) 抗精神病薬としての7−[4−(4−クロロベンジルオキシ)ベンゼンスルホニル]−8−メトキシ−3−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンゾアゼピニウムマレエートもしくはトシレート
JP2005517705A (ja) ベンゼンスルホンアミド誘導体ならびにドーパミンd3およびd2受容体リガンドとしてのその使用
TW200901979A (en) Compounds which have activity at M1receptor and their uses in medicine
TW200524875A (en) Benzazepine derivatives as monoamine oxidase B inhibitors
KR20080011400A (ko) 벤즈아제피늄 말레에이트 유도체의 결정질 형태
JP2005531580A (ja) 抗精神病薬としての7−フェニルスルホニル−テトラヒドロ−3−ベンゾアゼピン誘導体
MXPA06006077A (en) 7-[4-(4 -chlorobenzyloxy) benzenesulfonyl]-8-methoxy -3-methyl-2, 3, 4, 5-tetrahydro -1h-3- benzazepinium maleate or tosylate as antipsychotics
TW200530188A (en) Novel compounds
JP2007505076A (ja) 抗精神病剤としての7−ヘテロアリールスルホニル−テトラヒドロ−3−ベンゾアゼピン誘導体
JP2007512286A (ja) 抗精神病薬としての7−フェニルスルホニル−テトラヒドロ−3−ベンズアゼピン誘導体
NZ739883B2 (en) 5-ht2c receptor agonists and compositions and methods of use
CN1446813A (zh) 新颖的二氢吲哚化合物、它们的制备方法和含有它们的药物组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060526

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid